CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
R-(-)-gossypol acetic aciddrug
Likely dose
R-(-)-gossypol acetic acid 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00848016
NCT00848016Phase 2Completed
CompareCT.gov

A Phase II Study of the Orally Administered Negative Enantiomer of Gossypol (AT-101) in Patients With Advanced Adrenocortical Carcinoma (ACC)

National Cancer Institute (NCI)·interventional·Posted Feb 20, 2009·Updated May 7, 2014

In Brief

A Phase 2 clinical trial evaluating R-(-)-gossypol acetic acid for Recurrent Adrenocortical Carcinoma and 2 related conditions. Completed, enrolled 29 participants across 2 sites.

Detailed Summary

This phase II trial is studying how well gossypol acetic acid works in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery. Drugs used in chemotherapy such as gossypol acetic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Adrenocortical Carcinoma, Stage III Adrenocortical Carcinoma, Stage IV Adrenocortical Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2009
Enrollment StartFeb 1, 2009
Primary CompletionMar 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 17.4 years ago

Interventions

R-(-)-gossypol acetic aciddrug

Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.